OccuLogix Rheo trial
This article was originally published in The Gray Sheet
Executive Summary
FDA approves an investigational device exemption for a 300-patient pivotal study of the firm's Rheo blood filtration system to treat the "dry" form of age-related macular degeneration, OccuLogix announces Jan. 29. Slated to begin this quarter, the multi-site, sham-controlled trial will evaluate vision improvement according to an acuity scale at one-year follow-up. The firm's previous trial for the device failed to meet its primary endpoint. Currently there is no FDA-approved treatment for dry AMD, which accounts for up to 90% of AMD patients, OccuLogix says...